CJC-1295
CJC-1295 is a synthetic GHRH analog used off-label to stimulate growth hormone release, with the strongest community traction around body-composition changes and sleep-quality improvements. Practitioners and users split on dosing: the shorter-acting “no DAC” form is commonly run at 100–500 mcg subcutaneously before bed across eight- to twelve-week cycles, while clinician-tier protocols with the DAC version typically use 1–2 mg each morning for three to four weeks. The clearest upfront tradeoff is that every trial in the registered program was withdrawn.
Research Evidence
Evidence shape
Clinical evidence for CJC-1295 is low-tier. Only one human trial was ever registered, and it was withdrawn before completion, leaving a 100 percent withdrawal rate and no posted results. Two indications are mapped—preclinical mechanistic research in animals and a single long-tail trial entry for HIV-associated lipodystrophy with visceral fat reduction—but neither has produced human outcome data, replicated findings, or any completed study to assess.
Anecdotal efficacy
Side effects
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How CJC-1295 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
- Timing
- unspecified
- Cycle
- unspecified
1 completed trial identified; trial dosing not reliably extracted from registry data.
- Frequency
- BID
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
Clinician protocols dose 1 mg–2 mg BID subQ (3 sources).
- Frequency
- weekly
- Timing
- unspecified
- Cycle
- unspecified
Reported doses span 250 µg–1 mg, most commonly 250 µg; most report weekly dosing.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Peptide feedback
0 forum repliesLive community discussion for CJC-1295, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.